VCAM1 and breast cancer: ATN-161 is a non–RGD peptide antagonist that blocks not only α5β1, but also αvβ3, significantly blunts macrophage activation, inhibits vascular cell adhesion protein 1 (VCAM-1) expression in atherosclerotic mice and reduces breast cancer metastasis [91,92].